MAXONA Pharmaceuticals today announced that the company has submitted an Investigational New Drug (IND) Application to the ...

The trial aims to assess the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with ...

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...

Key Points GAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13. GAAP revenue of $5.5 million in Q2 2025 missed expectations by 26%. Advanced key clinical programs, with first U.S.

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...

Investing.com -- The U.S. Food and Drug Administration launched a new program called FDA PreCheck on Thursday to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign ...

Aurinia Pharmaceuticals Inc. achieved record Lupkynis sales of $66.6M in Q2 while managing cash flow. Click for insights on ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand ...

HONOLULU (HawaiiNewsNow) - The state Department of Health is offering free courses to a limited number of licensed healthcare ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

“This project is about using AI to automate and improve the early stages of drug development, particularly antibody design,” ...